AG-490 [133550-30-8]

Catalog number: HY-12000_200mg
Brand: MedChem Express
Packing: 200 mg
Other sizes: Other sizes available
Price: € 263.00
Expected delivery time: 10 days

Product specifications for - AG-490 [133550-30-8]

Product group: Chemicals
Category: Other
CAS No.: 133550-30-8
Purity: >98%
Molecular Formula: C17H14N2O3
Molecular weight: 294.30
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352200
Scientific information: 
Scientific info: AG-490 (Tyrphostin AG 490) is an inhibitor of EGFR with IC50 of 0.1 uM, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src. IC50 value: 0.1 uM (EGFR)[1], 10 uM (JAK2) [2] Target: EGFR in vitro: Corresponding to the specific dose-dependent inhibition of constitutively activated JAK2 in pre-B acute leukemia (ALL) cells, AG-490 (5 uM) almost completely blocks the growth of all ALL cells by inducing programmed cell death, with no deleterious effect on normal hematopoiesis. AG-490 does not inhibit the activities of Lck, Lyn, Btk, Syk, and Src [2]. AG-490 significantly inhibits the constitutive activation of Stat3 in MOPC, MPC11, and S194 cells, leading to dramatic dose-dependent apoptosis [3]. in vivo: Administration of AG-490 drastically reduces the numbers of CD45+ and HLA-DR+ cells from 48 % and 46% in bone marrow of untreated mice, as well as 38% and 22% in the spleen of untreated mice to undetectale levels [2]. In vivo administration of AG-490 causes murine myeloma tumor cell apoptosis but does not inhibit IL-12-mediated macrophage activation and IFN-gamma production by lymphocytes [3].
Safety information: 
Additional information: 
Synonyms: HY-12000
Transl Oncol. 2018 Dec 26;12(3):485-492. Read more
Stem Cell Res Ther. 2021 Oct 18;12(1):544. Read more
Sci Rep. 2020 Jul 9;10(1):11269. Read more
Reprod Sci. 2019 Jun;26(6):829-838. Read more
Reprod Biol Endocrinol. 2018 May 31;16(1):55. Read more
Phytomedicine. 2020 Apr;69:153194. Read more
Oncotargets Ther. 2021 May 28;14:3487-3501. Read more
Oncogene. 2017 May 25;36(21):2946-2956. Read more
Onco Targets Ther. 2019 Jul 5;12:5323-5334. Read more
Mol Med Rep. 2022 Mar;25(3):76. Read more